Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578352 | 0.99 | CETP (0.70) | CETP | |
| SCHEMBL4578635 | 0.89 | CETP (0.68) | CETP | |
| SCHEMBL4578534 | 0.88 | CETP (0.67) | CETP | |
| SCHEMBL10037999 | 0.88 | CETP (0.54) | CETP | |
| SCHEMBL4580111 | 0.88 | CETP (0.72) | CETP | |
| SCHEMBL714479 | 0.87 | CETP (0.70) | CETP | |
| SCHEMBL14491048 | 0.86 | CETP (0.58) | CETP | |
| SCHEMBL993541 | 0.85 | CETP (0.57) | CETP | |
| SCHEMBL973875 | 0.85 | CETP (0.61) | CETP | |
| SCHEMBL969728 | 0.84 | CETP (0.54) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-1828137-B1 | 4-CYCLOALKYL-SUBSTITUTED TETRAHYDROCHINOLINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-1828137-B1 | 4-CYCLOALKYL-SUBSTITUTED TETRAHYDROCHINOLINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1828137-A1 | 4-CYCLOALKYL-SUBSTITUTED TETRAHYDROCHINOLINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | Bayer HealthCare AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-20070142420-A1 | 4-HETEROARYL-TETRAHYDROQUINOLINES AND THEIR USE AS INHIBITORS OF THE CHOLESTERIN-ESTER TRANSFER PROTEIN | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142420-A1 | 4-HETEROARYL-TETRAHYDROQUINOLINES AND THEIR USE AS INHIBITORS OF THE CHOLESTERIN-ESTER TRANSFER PROTEIN | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7192971-B2 | 4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein | BAYER AKTIENGESELLSCHAFT (DE) | 2007-03-20 | — | — | US | disclosed |
| US-7192971-B2 | 4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein | BAYER AKTIENGESELLSCHAFT (DE) | 2007-03-20 | — | — | US | disclosed |
| WO-2006063828-A1 | 4-CYCLOALKYL-SUBSTITUTED TETRAHYDROCHINOLINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142420-A1 | 4-HETEROARYL-TETRAHYDROQUINOLINES AND THEIR USE AS INHIBITORS OF THE CHOLESTERIN-ESTER TRANSFER PROTEIN | CETP, HMGCR, CHLSN | CETP 1/4885 |
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | CETP, MTTP, HDLBP | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.